Spatial structure impacts adaptive therapy by shaping intra-tumoral competition.
Cancer therapeutic resistance
Dynamical systems
Prostate cancer
Tumour heterogeneity
Journal
Communications medicine
ISSN: 2730-664X
Titre abrégé: Commun Med (Lond)
Pays: England
ID NLM: 9918250414506676
Informations de publication
Date de publication:
2022
2022
Historique:
received:
12
08
2021
accepted:
28
03
2022
entrez:
23
5
2022
pubmed:
24
5
2022
medline:
24
5
2022
Statut:
epublish
Résumé
Adaptive therapy aims to tackle cancer drug resistance by leveraging resource competition between drug-sensitive and resistant cells. Here, we present a theoretical study of intra-tumoral competition during adaptive therapy, to investigate under which circumstances it will be superior to aggressive treatment. We develop and analyse a simple, 2-D, on-lattice, agent-based tumour model in which cells are classified as fully drug-sensitive or resistant. Subsequently, we compare this model to its corresponding non-spatial ordinary differential equation model, and fit it to longitudinal prostate-specific antigen data from 65 prostate cancer patients undergoing intermittent androgen deprivation therapy following biochemical recurrence. Leveraging the individual-based nature of our model, we explicitly demonstrate competitive suppression of resistance during adaptive therapy, and examine how different factors, such as the initial resistance fraction or resistance costs, alter competition. This not only corroborates our theoretical understanding of adaptive therapy, but also reveals that competition of resistant cells with each other may play a more important role in adaptive therapy in solid tumours than was previously thought. To conclude, we present two case studies, which demonstrate the implications of our work for: (i) mathematical modelling of adaptive therapy, and (ii) the intra-tumoral dynamics in prostate cancer patients during intermittent androgen deprivation treatment, a precursor of adaptive therapy. Our work shows that the tumour's spatial architecture is an important factor in adaptive therapy and provides insights into how adaptive therapy leverages both inter- and intra-specific competition to control resistance.
Sections du résumé
Background
UNASSIGNED
Adaptive therapy aims to tackle cancer drug resistance by leveraging resource competition between drug-sensitive and resistant cells. Here, we present a theoretical study of intra-tumoral competition during adaptive therapy, to investigate under which circumstances it will be superior to aggressive treatment.
Methods
UNASSIGNED
We develop and analyse a simple, 2-D, on-lattice, agent-based tumour model in which cells are classified as fully drug-sensitive or resistant. Subsequently, we compare this model to its corresponding non-spatial ordinary differential equation model, and fit it to longitudinal prostate-specific antigen data from 65 prostate cancer patients undergoing intermittent androgen deprivation therapy following biochemical recurrence.
Results
UNASSIGNED
Leveraging the individual-based nature of our model, we explicitly demonstrate competitive suppression of resistance during adaptive therapy, and examine how different factors, such as the initial resistance fraction or resistance costs, alter competition. This not only corroborates our theoretical understanding of adaptive therapy, but also reveals that competition of resistant cells with each other may play a more important role in adaptive therapy in solid tumours than was previously thought. To conclude, we present two case studies, which demonstrate the implications of our work for: (i) mathematical modelling of adaptive therapy, and (ii) the intra-tumoral dynamics in prostate cancer patients during intermittent androgen deprivation treatment, a precursor of adaptive therapy.
Conclusion
UNASSIGNED
Our work shows that the tumour's spatial architecture is an important factor in adaptive therapy and provides insights into how adaptive therapy leverages both inter- and intra-specific competition to control resistance.
Identifiants
pubmed: 35603284
doi: 10.1038/s43856-022-00110-x
pii: 110
pmc: PMC9053239
doi:
Types de publication
Journal Article
Langues
eng
Pagination
46Subventions
Organisme : NCI NIH HHS
ID : U01 CA232382
Pays : United States
Informations de copyright
© The Author(s) 2022.
Déclaration de conflit d'intérêts
Competing interestsThe authors declare no competing interests. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.
Références
Insights Imaging. 2012 Dec;3(6):573-89
pubmed: 23093486
EBioMedicine. 2019 Oct;48:178-190
pubmed: 31594749
Eur J Cancer. 2016 Nov;67:213-222
pubmed: 27689717
Cancer Res. 2020 Dec 1;80(23):5147-5154
pubmed: 32934022
Eur J Cancer. 1967 Nov;3(4):381-7
pubmed: 6078937
Proc Natl Acad Sci U S A. 2020 Jul 28;117(30):17924-17931
pubmed: 32661175
Nat Genet. 2020 Jun;52(6):604-614
pubmed: 32424351
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
BMC Bioinformatics. 2019 Dec 16;20(1):710
pubmed: 31842729
Cancer Res. 2009 Jun 1;69(11):4894-903
pubmed: 19487300
Cancer Res. 2015 Apr 15;75(8):1567-79
pubmed: 25878146
Cancer Res. 2021 Feb 15;81(4):811-812
pubmed: 33822746
Nat Commun. 2021 Apr 6;12(1):2060
pubmed: 33824323
ISME J. 2021 Oct;15(10):3019-3033
pubmed: 33953363
Commun Med (Lond). 2022 Apr 25;2:46
pubmed: 35603284
Mol Oncol. 2014 Sep 12;8(6):1095-111
pubmed: 25087573
Cancer Discov. 2018 Oct;8(10):1270-1285
pubmed: 30166348
Nat Commun. 2020 Apr 9;11(1):1750
pubmed: 32273504
Eur J Cancer. 1973 Apr;9(4):305-12
pubmed: 4360278
Cancer Res. 2019 Jul 15;79(14):3776-3788
pubmed: 31113818
Cold Spring Harb Perspect Med. 2020 Nov 2;10(11):
pubmed: 33139405
Nat Ecol Evol. 2022 Feb;6(2):207-217
pubmed: 34949822
Radiat Oncol. 2015 Jul 31;10:159
pubmed: 26227259
Nat Rev Clin Oncol. 2015 Nov;12(11):664-75
pubmed: 26169924
Cancer Res. 2020 Apr 1;80(7):1578-1589
pubmed: 31948939
J Theor Biol. 2009 Mar 21;257(2):292-302
pubmed: 19135065
Br J Cancer. 2019 Oct;121(7):556-566
pubmed: 31417189
Math Biosci. 1992 Jul;110(2):201-19
pubmed: 1498450
Cancer Res. 1987 Jan 15;47(2):414-8
pubmed: 3539322
Cold Spring Harb Perspect Med. 2018 Mar 1;8(3):
pubmed: 28710258
Cancer Res. 2018 Apr 15;78(8):2127-2139
pubmed: 29382708
Nat Rev Clin Oncol. 2014 Jun;11(6):365-76
pubmed: 24840076
Nat Methods. 2020 Mar;17(3):261-272
pubmed: 32015543
J Environ Manage. 2005 Aug;76(3):210-20
pubmed: 15922504
PLoS Biol. 2020 May 15;18(5):e3000713
pubmed: 32413038
Cancer Res. 2021 Feb 15;81(4):1135-1147
pubmed: 33172930
Cancers (Basel). 2021 Feb 16;13(4):
pubmed: 33669315
J Math Biol. 2021 Oct 11;83(5):47
pubmed: 34632539
PLoS Comput Biol. 2013;9(2):e1002916
pubmed: 23468606
Evol Appl. 2020 Aug 06;13(7):1660-1672
pubmed: 32821276
J Theor Biol. 2018 Oct 14;455:249-260
pubmed: 30048718
Nat Ecol Evol. 2021 Jun;5(6):826-835
pubmed: 33846605
Nat Commun. 2017 Nov 28;8(1):1816
pubmed: 29180633
Nat Rev Cancer. 2013 Oct;13(10):714-26
pubmed: 24060863
N Engl J Med. 2013 Apr 4;368(14):1314-25
pubmed: 23550669
PLoS Comput Biol. 2022 Mar 9;18(3):e1009919
pubmed: 35263336
Evol Appl. 2020 Jul 18;13(7):1558-1568
pubmed: 32821272
Science. 2016 Jan 1;351(6268):aad3292
pubmed: 26722002
Sci Transl Med. 2016 Feb 24;8(327):327ra24
pubmed: 26912903
Bull Math Biol. 2018 Jul;80(7):1776-1809
pubmed: 29736596
PLoS Biol. 2017 Feb 9;15(2):e2001110
pubmed: 28182734
J Theor Biol. 2013 Oct 21;335:235-44
pubmed: 23850479
Elife. 2020 Mar 24;9:
pubmed: 32207406
Phys Rev E. 2021 Mar;103(3-1):032408
pubmed: 33862722
PLoS Pathog. 2014 Jun 26;10(6):e1004225
pubmed: 24968123
Genetics. 2020 Sep;216(1):191-203
pubmed: 32661138
Clin Cancer Res. 2019 Jul 15;25(14):4413-4421
pubmed: 30992299
N Engl J Med. 2012 Sep 6;367(10):895-903
pubmed: 22931259
Bull Math Biol. 2020 Jan 17;82(1):15
pubmed: 31953602
Nat Commun. 2017 Dec 8;8(1):1995
pubmed: 29222471
Commun Biol. 2019 Aug 8;2:301
pubmed: 31428689
Nat Commun. 2016 Oct 03;7:12760
pubmed: 27694797
Nat Ecol Evol. 2019 Jul;3(7):996-998
pubmed: 31235925
Nat Rev Cancer. 2004 Jun;4(6):423-36
pubmed: 15170445
Cancer. 2006 Jul 15;107(2):389-95
pubmed: 16783817
Nat Rev Drug Discov. 2020 Apr;19(4):221-223
pubmed: 32203291
Nat Ecol Evol. 2019 Jan;3(1):125-134
pubmed: 30510177
Cancer Res. 2012 Dec 15;72(24):6362-70
pubmed: 23066036
Biomolecules. 2021 Dec 21;12(1):
pubmed: 35053156
Nature. 2009 May 28;459(7246):508-9
pubmed: 19478766
PLoS Comput Biol. 2020 Mar 10;16(3):e1007635
pubmed: 32155140